Medicare utilization — DR. DANIEL A PATTERSON (MD,PHD, MRCP,)
Calendar year 2023 · data refreshed 2026-05-27
| HCPCS | Description | Services | Beneficiaries | Allowed | Payment |
|---|---|---|---|---|---|
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 70,380 | 56 | $0 | $27,917 |
| J0897 | Injection, denosumab, 1 mg | 7,920 | 35 | $0 | $146,253 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 6,748 | 86 | $0 | $656 |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | 5,660 | 21 | $0 | $35,281 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 4,229 | 36 | $0 | $317 |
Service volume and Medicare payment amounts do not indicate quality of care, patient outcomes, or fraud. Data reflects Medicare fee-for-service only.
Source: CMS public data · Not endorsed by CMS · Beneficiary counts under 11 are suppressed in source data ·